rosiglitazone has been researched along with mifepristone in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brune, M; Bush, E; Chiou, W; Fung, S; Imade, H; Jacobson, P; Knourek-Segel, V; Kurukulasuriya, R; Link, JT; Monzon, K; Nguyen, PT; Shapiro, R; Stolarik, D; Wang, J; Wilcox, D; Yeh, VS | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Goya, K; Kasayama, S; Kawase, I; Kitamura, T; Kouhara, H; Kurebayashi, S; Saito, H; Sumitani, S; Xu, X; Yamamoto, H | 1 |
| Andrew, R; Homer, NZ; Karpe, F; Stimson, RH; Tan, GD; Wake, DJ; Walker, BR | 1 |
| Berry, A; D'Acquisto, F; Ianaro, A; Matthews, L; Ray, D; Tersigni, M | 1 |
| Benthem, L; Boersma, G; Scheurink, AJ; Steimer, TJ; van Dijk, G | 1 |
| Arango-Rodriguez, M; Conget, P; Contador, D; Espinosa, M; Ezquer, F; Puebla, C; Sobrevia, L | 1 |
| Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
| Atlas, E; Peshdary, V | 1 |
1 review(s) available for rosiglitazone and mifepristone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for rosiglitazone and mifepristone
| Article | Year |
|---|---|
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Cortisone; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Fenofibrate; Gas Chromatography-Mass Spectrometry; Hormone Antagonists; Humans; Hydrocortisone; Hypolipidemic Agents; Insulin Resistance; Kinetics; Liver; Male; Metyrapone; Microdialysis; Middle Aged; Mifepristone; Obesity; PPAR alpha; PPAR gamma; Rosiglitazone; Subcutaneous Fat; Thiazolidinediones | 2007 |
11 other study(ies) available for rosiglitazone and mifepristone
| Article | Year |
|---|---|
Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Administration, Oral; Animals; Humans; Lactams; Metabolic Syndrome; Mice | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.
Topics: Animals; Aorta; Bezafibrate; Cattle; Cells, Cultured; Dactinomycin; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Fenofibrate; Gene Expression Regulation, Enzymologic; Half-Life; Mifepristone; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrimidines; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Transfection | 2004 |
Thiazolidinediones are partial agonists for the glucocorticoid receptor.
Topics: Cell Division; Cell Line, Tumor; Dexamethasone; Enzyme Activation; Genes, Reporter; HeLa Cells; Hormone Antagonists; Humans; Luciferases; Lung Neoplasms; Mifepristone; PPAR gamma; Receptors, Glucocorticoid; Rosiglitazone; Thiazolidinediones; Transfection | 2009 |
Pharmacological treatment of hyperinsulineamia in rats depends on coping style.
Topics: Adaptation, Psychological; Animals; Blood Glucose; Disease Susceptibility; Glucose Tolerance Test; Hyperinsulinism; Hypoglycemic Agents; Insulin; Male; Mifepristone; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
FDA puts restrictions on use of controversial diabetes drug.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug and Narcotic Control; Drug Approval; Drug Industry; Drug Prescriptions; Humans; Hypoglycemic Agents; Mifepristone; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2011 |
Dexamethasone and rosiglitazone are sufficient and necessary for producing functional adipocytes from mesenchymal stem cells.
Topics: Adipocytes; Adipogenesis; Anilides; Animals; CCAAT-Enhancer-Binding Proteins; Cell Differentiation; Cricetinae; Dexamethasone; Dogs; Humans; In Vitro Techniques; Mesenchymal Stem Cells; Mesocricetus; Mice; Mice, Inbred C57BL; Mifepristone; PPAR gamma; Rabbits; Rats; Rats, Wistar; Receptors, Glucocorticoid; RNA, Messenger; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2015 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
Dexamethasone induced miR-155 up-regulation in differentiating 3T3-L1 preadipocytes does not affect adipogenesis.
Topics: 3T3 Cells; Adipocytes; Adipogenesis; Animals; Dexamethasone; Glucocorticoids; Mice; MicroRNAs; Mifepristone; Rosiglitazone; Up-Regulation | 2018 |